<DOC>
	<DOCNO>NCT01214655</DOCNO>
	<brief_summary>This study multicenter , nonrandomized , open-label , dose-escalation intra-patient dose-escalation , Phase 1 study intravenous LY2523355 determine dose LY2523355 safely administer patient acute leukemia . Part A Part B dose escalation two schedule patient acute leukemia . Parts A B enroll concurrently . Part C dose expansion schedule patient acute myeloblastic leukemia ( AML ) .</brief_summary>
	<brief_title>A Study Patients With Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Dose escalation period schedule : Patient must confirm diagnosis acute leukemia regardless subtype experimental phase 1 therapy appropriate Are great equal 18 year age Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Females childbearing potential must negative urine serum pregnancy test less equal 7 day prior first dose study drug Dose confirmation period schedule : Participant must confirm diagnosis untreated AML , candidate standard therapy , clinical trial prefer treatment option acute AML relapse refractory 2 prior induction regimen . Hydroxyurea control prior blast count consider prior regimen . Are great equal 60 year age Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Females childbearing potential must negative urine serum pregnancy test less equal 7 day prior first dose study drug Have receive treatment within 28 day initial dose study drug drug receive regulatory approval indication . Participants known central nervous system ( CNS ) leukemia spinal fluid cytology image . A lumbar puncture require unless CNS involvement clinically suspect . Participants sign symptom leukemic meningitis history leukemic meningitis must negative lumbar puncture within 2 week study enrollment . Have active malignancy ( exception basal squamous cell skin cancer ) time study entry Have autologous allogenic bone marrow transplant within 3 month . All organ toxicity must resolve . Have evidence graftversushost disease due allogenic bone marrow transplant Have uncontrolled systemic infection Females pregnant lactate Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) ( screen require )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia , Blast Crisis</keyword>
</DOC>